Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome
نویسندگان
چکیده
Rotigotine, a nonergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMA and FDA marketing authorization for the treatment of adult patients with early or advanced Parkinson’s disease or with moderate-to-severe restless legs syndrome (RLS). This review comprises an overview of the pharmacokinetics, the pharmacodynamics and the clinical efficacy and safety of the rotigotine transdermal patch for RLS. Its source material was identified by a PubMed search for the terms ‘rotigotine’ and ‘RLS’. The rotigotine transdermal patch demonstrates clinical efficacy alongside a good tolerability profile. Application site reactions were the most frequent adverse events, and they were considered mild to moderate in the majority of cases. In summary, the rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of RLS. Further studies should focus on the possibility that continuous dopamine stimulation by means of transdermal patches might have an influence on RLS augmentation rates. © 2014 S. Karger AG, Basel
منابع مشابه
Rotigotine transdermal system: a short review
Rotigotine (Neupro((R))) is a new non-ergolinic dopamine agonist transdermal patch that can be applied once daily. To date, it is approved for the treatment of early Parkinson's disease as monotherapy and has been shown to be effective in the treatment of advanced-stage Parkinson's disease and restless legs syndrome in several clinical trials. This review gives an overview of physical, chemical...
متن کاملAn Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a transdermal patch providing continuous drug delivery over 24 h, with a plasma conce...
متن کاملTransdermal rotigotine for the perioperative management of restless legs syndrome
BACKGROUND Immobilisation, blood loss, sleep deficiency, and (concomitant) medications during perioperative periods might lead to acute exacerbation of symptoms in patients with the restless legs syndrome (RLS). Continuous transdermal delivery of the dopamine agonist rotigotine provides stable plasma levels over 24 h and may provide RLS patients with a feasible treatment option for perioperativ...
متن کاملAbsorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.
The dopamine agonist rotigotine was developed for the treatment of Parkinson's disease and restless legs syndrome. Disposition, metabolism, elimination, and absolute bioavailability of rotigotine were determined in six healthy male subjects by using two different forms of administration in a randomized sequence with a crossover design. Treatment A (continuous infusion) consisted of a single rad...
متن کاملAuthor's response to reviews Title: Transdermal rotigotine for the perioperative management of restless legs syndrome Authors:
1) Study's objective is "To assess rotigotine transdermal patch for the perioperative management of moderate to severe RLS". To assess what? Efficacy? Feasibility of use? The objective of this posthoc analysis was to assess the feasibility of use of rotigotine transdermal patch for the perioperative management of moderate to severe RLS. Efficacy data for the entire study population, including p...
متن کامل